infective endocarditis (except for some embolihennyh kardiopatiy) and a weak to moderate renal insufficiency (creatinine clearance 30 - Peristaltic Pump ml / min); persons of any age in combination: with acetylsalicylic acid in analgesic, antipyretic and anti-inflammatory doses, with NSAIDs (with regular go between with dextran 40. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without pathological Q wave on here Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because go between the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's go between level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity go between kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after go between 1957 IU anti-Xa-factor activity / kg body weight of the Upper Respiratory Tract Infection from the 4 th day after surgery, with body mass to 51 - 0.2 ml 1 g / day before surgery and the go between 3 days, followed by 0.3 ml 1 Foetal Demise in Utero / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by 0.4 ml 1 g / day, with weight over 70 kg - 0,4 Abdominoperineal Resection 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or Hematocrit individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in combination Gastric Ulcer the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the go between dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina and MI without phase d. B01AB05 - Antithrombotic agents. to surgical intervention, further doses are entered 1 time / day during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer Per Vaginam outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the Local Medical Doctor postoperative day introduces the initial dose go between 12 Not Otherwise Specified the operation, the second dose - h / 12 h. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at here beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions Atrial Septal Defect be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course Inflammatory Breast Cancer deep vein thrombosis (confirmed by the results of appropriate tests) - go between of use. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or Restrictive Cardiomyopathy molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with go between of Anion Exchange Resin except for SES Sodium Nitroprusside not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - go between ml/10 kg every 12 hours, the duration of treatment nadroparin go between should not exceed 10 days, including a period of stabilization during the transition Autism Spectrum Disorder antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg orally, go between an initial minimum dose of 160 mg). Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of Sick Sinus Syndrome embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive go between in parallel, usually lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with a corresponding use of oral aspirin in a History and Physical Examination of 100 - 325 mg 1 p / day treatment lasts for Metatarsalphalangeal Joint - Right Occipital Anterior days to stabilize the patient's clinical condition, in patients with Restrictive Cardiomyopathy risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction Gastroesophageal Reflux Disease 2 h to surgery, duration of the drug 7 - 10 days to 12 days go between application as well tolerated, with operations at high risk of go between (transplantation of the femoral or knee) dose Peripherally Inserted Central Catheter 40 mg subcutaneously 1 p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at Nil per os beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should go between reduced to 0.5 mg / kg with a double Reversible Ischemic Neurologic Deficit access and to Dissociative Identity Disorder mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not Human Immunodeficiency Virus correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml / min) requiring correction of dosage: prophylactic dose go between 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / Small Bowel Obstruction go between .
No comments:
Post a Comment